Specify a stock or a cryptocurrency in the search bar to get a summary
Medesis Pharma SA
ALMDPMedesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France. Address: L?Orée des Mas, Montpellier, France, 34670
Analytics
WallStreet Target Price
2.98 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALMDP
Dividend Analytics ALMDP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALMDP
Stock Valuation ALMDP
Financials ALMDP
Results | 2019 | Dynamics |